Develops therapies for neurological disorders, focusing on innovative treatments.
Tectonic Therapeutic Inc. is a pioneering gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative hematopoietic stem cell gene therapies for rare diseases. Leveraging advanced technology, Tectonic Therapeutic focuses on modifying hematopoietic stem cells extracted from patients using lentiviral vectors. This process aims to introduce functional copies of genes mutated in specific diseases.
At the core of Tectonic Therapeutic's pipeline are several promising therapies. AVR-RD-02 is currently in Phase 1/2 clinical trials for Gaucher disease type 1 and 3, while AVR-RD-01 is undergoing Phase 2 clinical trials for Fabry disease. Additionally, AVR-RD-03 is in the preclinical stage, targeting Pompe disease. These initiatives underscore Tectonic Therapeutic's commitment to developing effective treatments for challenging rare diseases.
Founded in 2015, Tectonic Therapeutic continues to drive innovation in gene therapy. With a dedicated team of experts and strategic partnerships, the company is poised to make significant advancements in the field, offering hope to patients and families affected by these debilitating conditions.